City

Hangzhou (1)

Nanjing (1)

Suzhou (1)

Condition

Abatacept (3)

Acute-graft-versus-host Disease (1)

Dermatomyositis (1)

Haplo-identical HCT (1)

Prevention (1)

Rheumatoid Arthritis (1)

Treatment Compliance (1)

Overall Status

Recruiting (3)

Sign in for free

Phase

early phase 1 (1)

phase 1/phase 2 (1)

phase 3 (1)

Sponsor

The First Affiliated Hospital of Soochow University (1)

The First Affiliated Hospital with Nanjing Medical University (1)

Zhejiang Provincial People's Hospital (1)

Collaborator

National Natural Science Foundation of China (1)

Intervention

abatacept (2)

higher dose of abatacept (1)

janus kinase inhibitor (1)

lower dose of abatacept (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (3)

abatacept

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting

Abatacept
+2 more

Janus Kinase Inhibitor
Abatacept

Hangzhou, Zhejiang, China

Zhejiang Provincial People's Hospital

Jul 5, 2022

Dermatomyositis, Abatacept Trial in Nanjing (Abatacept)

Recruiting

Dermatomyositis
Abatacept

Abatacept

Nanjing, Jiangsu, China

The First Affiliated Hospital with Nanjing Medical University

Jun 29, 2021

Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT Trial in Suzhou (Lower dose of abatacept, Higher dose of

Recruiting

Abatacept
+3 more

Lower dose of abatacept
Higher dose of abatacept

Suzhou, Jiangsu, China

the First Affiliated Hospital of Soochow University

Jun 1, 2021